Hosted on MSN1d
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...
Positive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program Advances
Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...
BioSpace3d
Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking as Top Candidate: Analysts
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
Should You Buy the Dip on This High-Flying Stock?
It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
BioSpace2d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Altimmune Could Find A Partner For Its Phase 3 Exercise
If Altimmune can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Click ...